- Home
- CPS vs ZNTL Comparison
CPS vs ZNTL Comparison
Compare CPS & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPS | ZNTL |
|---|---|---|
| Founded | 1960 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.6M | 118.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CPS | ZNTL |
|---|---|---|
| Price | $33.20 | $1.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $39.00 | $5.87 |
| AVG Volume (30 Days) | 116.3K | ★ 766.1K |
| Earning Date | 02-12-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $2,729,297,000.00 | $26,865,000.00 |
| Revenue This Year | $0.22 | N/A |
| Revenue Next Year | $6.65 | N/A |
| P/E Ratio | $17.99 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.38 | $1.01 |
| 52 Week High | $40.67 | $3.33 |
Technical Indicators
Market Signals| Indicator | CPS | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 45.25 |
| Support Level | $29.67 | $1.33 |
| Resistance Level | $35.62 | $1.46 |
| Average True Range (ATR) | 1.27 | 0.07 |
| MACD | 0.14 | -0.00 |
| Stochastic Oscillator | 61.18 | 21.87 |
Price Performance
Historical ComparisonAbout CPS Cooper-Standard Holdings Inc.
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.